Developer docs
API playgroundTry for free, no card

Search company profiles

Solarea Bio

Full company profile

uuid0000cyu

Namestring
Solarea Bio
Legal namestring
Sōlaria Biō, Inc.
Websiteurl
solareabio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Solarea Bio, Inc. (also operating as Sōlaria Biō and formerly known as Journa Health) is a privately held Delaware-incorporated biotechnology company headquartered in Waltham, Massachusetts, that develops microbial-based medical foods derived from beneficial microbes found in fruits and vegetables. Its core product, Bōndia™, is an FDA-classified medical food formulated as a synbiotic — combining four proprietary plant-sourced probiotic strains (Levilactobacillus brevis SBS04254, Leuconostoc mesenteroides SBS04255, Lactiplantibacillus plantarum SBS04260, and the yeast Pichia kudriavzevii SBS04263) with prebiotic fibers (organic blueberry powder and oligofructose from chicory root) and algae-derived Vitamin D3 — delivered via a precision-release capsule designed to survive gastric acid and reach the gut alive. The product targets the gut–bone axis in postmenopausal and osteopenic women, with a peer-reviewed 286-woman 12-month double-blind RCT published in Osteoporosis International (2025) reporting an 85% reduction in femoral neck bone loss, a 73.7% reduction in hip bone loss in women with BMI ≥30, and a 78.9% reduction in severe GI symptoms.

The company generates revenue through a hybrid direct-to-consumer and B2B2C model. Bōndia is sold primarily through the company's Shopify-hosted e-commerce storefront (solaria.bio) via subscription tiers priced from $83/month (annual plan, $999/year) up to $125/month for one-time purchases, with a 30-day money-back guarantee and HSA/FSA eligibility. A practitioner affiliate program channels healthcare-provider recommendations through unique referral links, complemented by a DexaFit partnership bundling DEXA bone-density screening with product subscriptions. The company has raised approximately $36M+ in disclosed equity capital across a 2018 seed round, a 2020 Series A (~$11.2M), a 2023 Series B first close of $15M led by S2G Ventures (targeting up to $25M), and additional SEC exempt-offering filings of $1M (2024) and $9.91M (2025), supplemented by a $3M NIH/National Institute on Aging grant. Management is led by CEO Catherine Balsam-Schwaber (appointed October 2025), with co-founder Eric Schott, PhD as COO and scientific leadership under VP of R&D Mark Charbonneau, PhD; the company employs 11–50 people and is preparing to launch Arthrīva, a second synbiotic medical food for rheumatoid arthritis, in Spring 2026.

Short descriptiontext

Solarea Bio is a privately held biotechnology company that develops FDA-classified synbiotic medical foods from plant-sourced microbes; it sells Bōndia, a clinically validated bone-health product, via DTC subscription and a practitioner affiliate channel to postmenopausal and osteopenic women in the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical foods, synbiotic supplements, bone health products, microbial therapeutics, gut-bone axis
Industry1 code
PRIMARYAFAKAJAD
Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium)
Agriculture & Food Production/Food Processing & Manufacturing/Specialty & Functional Foods Manufacturing (Organic, Fortified, Medical Foods)
NAICS code1 code
  • Fruit and Vegetable Canning, Pickling, and Drying31142
SIC code1 code
  • Food And Kindred Products2000
Product category
Medical Foods / Synbiotic Supplements
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct-to-Consumer Product Sales
TypeSubscription Recurring
Description

Primary revenue stream from selling Bōndia synbiotic medical food directly to consumers through the company's e-commerce website. Products available as one-time purchases or subscription plans with recurring billing. Subscription model provides predictable recurring revenue with discounts for longer commitments.

solaria.bio
2One-Time Product Purchases
TypeOne Time License
Description

Single-month supply purchases available for consumers who prefer not to commit to subscriptions. Priced at $125/month for one-time buyers.

solaria.bio
3Practitioner Affiliate Referrals
TypeAffiliate Referral
Description

Healthcare providers earn commissions when they refer patients who purchase Bōndia through their unique affiliate link or code. Practitioners can apply to join the program and receive sample products to aid recommendations.

igrownews.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details5 tiers
1Monthly subscription - $110/month
ModelSubscriptionBilling cadenceMonthly
Notes

1-month supply delivered monthly. Subscribe and save 12% vs one-time purchase. First shipment includes free starter kit. Pause, cancel or change shipping date anytime.

solaria.bio
23-Month Supply - $94/month ($282 total)
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Save 25% vs one-time purchase. 3 pouches delivered every 3 months. Free shipping included. First shipment includes free starter kit.

solaria.bio
3Annual Supply - $83/month ($999 total)
ModelSubscriptionBilling cadenceAnnual
Notes

Save 38% vs one-time purchase. 12-month one-time purchase for $999. Lowest monthly price. Most popular for clinical results. 4 shipments over 12 months with free shipping.

solaria.bio
4One-Time Purchase - $125/month
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Single 1-month supply purchased without subscription commitment. No subscription required.

solaria.bio
5Gift Subscription - $999 (1-Year)
ModelSubscriptionBilling cadenceAnnual
Notes

Special offer: Get $75 off gift purchase. Code GIFTMOM for additional $250 savings. 12-month subscription as a gift.

solaria.bio
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Solarea Bio develops and sells FDA-regulated microbial medical foods. Its flagship product Bōndia is a plant-sourced synbiotic combining four proprietary probiotic strains with prebiotic fibers and algae-derived Vitamin D3, clinically proven to reduce bone loss in postmenopausal women via the gut-bone axis. The company sells direct-to-consumer via its website and through a practitioner affiliate channel.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 85% reduction in femoral neck bone loss in women with osteopenia after 12 months of consistent use
+4 more records
Product overview1 text field

Solarea Bio (formerly Journa Health) is a biotechnology company offering a portfolio of microbial-based medical foods derived from beneficial microbes found in fruits and vegetables. The core product is Bōndia™, a plant-sourced synbiotic medical food clinically proven to reduce bone loss by targeting the gut-bone axis. The company is also developing Arthrīva, a product for rheumatoid arthritis expected in Spring 2026. Bōndia is positioned as a medical food (held to higher FDA safety and efficacy standards) rather than a dietary supplement, and is available via direct-to-consumer subscription through the company's Shopify-hosted website.

Product and service1 record
1Bōndia™
CategoryMedical Food / Synbiotic
Description

A plant-sourced, living synbiotic medical food designed to reduce bone loss in postmenopausal women by targeting the gut-bone axis. Contains four proprietary probiotic strains (Lactiplantibacillus plantarum SBS04260, Levilactobacillus brevis SBS04254, Leuconostoc mesenteroides SBS04255, Pichia kudriavzevii SBS04263) combined with prebiotic fibers from blueberry, chicory root, and algae-derived Vitamin D3. Sold as a medical food (FDA-regulated, higher standard than supplements) via direct-to-consumer subscription.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Harvard Medical School
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Ongoing research partnership referenced in company materials. Clinical trial results and ongoing Harvard Medical School partnership reflect the company's commitment to uncompromising science and clinical validation.

solaria.bio
2DexaFit
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for bone density screening services. Offers bundled bone health packages combining DexaFit DEXA scans with Sōlaria Bio product subscriptions. Free DEXA scans included with product subscriptions at select locations.

solaria.bio
Strategic tierMinorTypeGTM or Marketing Partner
Description

Wellness healthcare provider featured as partner logo on website. Dr. Robin Berzin, Parsley Health founder, has spoken publicly about her personal osteopenia diagnosis and recommends Bōndia.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Partner logo displayed on company website, indicating a marketing or referral relationship with this wellness healthcare provider.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Partner logo displayed on company website, indicating a marketing or referral relationship with this digital health platform.

6Goal Daily
Strategic tierMinorTypeGTM or Marketing Partner
Description

Partner logo displayed on company website, indicating a marketing or referral relationship with this wellness brand.

solaria.bio
Strategic tierMinorTypeGTM or Marketing Partner
Description

Wellness media brand featured as partner logo on website, suggesting content marketing or referral partnership.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pendulum sells clinically validated, multi-strain synbiotic products via DTC subscription targeting specific conditions (e.g., metabolic health, glucose control). Closely comparable to Solarea Bio on proprietary probiotic strains, clinical evidence-based marketing, and direct subscription model.

TypeDirect peer
Description

Seed Health develops proprietary synbiotic formulations with patented strains and sells via DTC subscription. Comparable on proprietary-strain IP, science-forward branding, and subscription GTM, though Seed targets gut microbiome health more broadly than Solarea's indication-specific positioning.

3Metagenics
TypeDirect peer
Description

Metagenics is a practitioner-channel medical food and supplement manufacturer with a strong focus on bone health, gut health, and inflammation. Closely comparable to Solarea Bio on FDA medical food positioning, practitioner/affiliate distribution model, and condition-specific functional foods.

TypeDirect peer
Description

Microbiome Labs distributes practitioner-channel probiotic and microbiome products, including clinically studied formulations like Megasporebiotic. Comparable to Solarea Bio on practitioner/affiliate GTM and science-driven probiotic formulations.

TypeBroad incumbent
Description

Thorne is a broad-line supplement brand sold through practitioners and DTC with strong clinical/athlete positioning. Comparable as a wider portfolio competitor in the practitioner-channel supplement market, though less indication-specific than Solarea Bio's medical food focus.

TypeDirect peer
Description

Designs for Health is a practitioner-channel supplement brand offering condition-specific protocols (including bone, gut, and inflammation). Comparable to Solarea Bio on practitioner affiliate distribution and clinician-focused selling motion.

TypeDirect peer
Description

Pure Encapsulations is a practitioner-grade supplement brand owned by Nestlé Health Science, sold through healthcare professionals with condition-specific lines. Comparable to Solarea Bio on practitioner-only distribution and hypoallergenic, science-led positioning.

TypeDirect peer
Description

Standard Process is a practitioner-channel whole-food supplement and medical food manufacturer. Comparable to Solarea Bio on practitioner distribution, condition-specific products, and medical food regulatory positioning.

TypeBroad incumbent
Description

Nestlé Health Science is a global medical nutrition incumbent offering medical foods across bone, digestive, and metabolic health (e.g., Peptamen, Resource, Optifast). Comparable as a broad medical-foods incumbent against which Solarea competes for category share and physician mind-share.

TypeBroad incumbent
Description

Novonesis (formerly Chr. Hansen) is a global probiotic and enzyme ingredient manufacturer with deep microbial strain IP. Comparable as a broader ingredient/probiotic incumbent that controls much of the upstream strain supply Solarea Bio relies upon.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solarea Bio

Medical Foods / Synbiotic Supplementssolareabio.com

Solarea Bio is a privately held biotechnology company that develops FDA-classified synbiotic medical foods from plant-sourced microbes; it sells Bōndia, a clinically validated bone-health product, via DTC subscription and a practitioner affiliate channel to postmenopausal and osteopenic women in the United States.

What Solarea Bio does

Solarea Bio, Inc. (also operating as Sōlaria Biō and formerly known as Journa Health) is a privately held Delaware-incorporated biotechnology company headquartered in Waltham, Massachusetts, that develops microbial-based medical foods derived from beneficial microbes found in fruits and vegetables. Its core product, Bōndia™, is an FDA-classified medical food formulated as a synbiotic — combining four proprietary plant-sourced probiotic strains (Levilactobacillus brevis SBS04254, Leuconostoc mesenteroides SBS04255, Lactiplantibacillus plantarum SBS04260, and the yeast Pichia kudriavzevii SBS04263) with prebiotic fibers (organic blueberry powder and oligofructose from chicory root) and algae-derived Vitamin D3 — delivered via a precision-release capsule designed to survive gastric acid and reach the gut alive. The product targets the gut–bone axis in postmenopausal and osteopenic women, with a peer-reviewed 286-woman 12-month double-blind RCT published in Osteoporosis International (2025) reporting an 85% reduction in femoral neck bone loss, a 73.7% reduction in hip bone loss in women with BMI ≥30, and a 78.9% reduction in severe GI symptoms.

The company generates revenue through a hybrid direct-to-consumer and B2B2C model. Bōndia is sold primarily through the company's Shopify-hosted e-commerce storefront (solaria.bio) via subscription tiers priced from $83/month (annual plan, $999/year) up to $125/month for one-time purchases, with a 30-day money-back guarantee and HSA/FSA eligibility. A practitioner affiliate program channels healthcare-provider recommendations through unique referral links, complemented by a DexaFit partnership bundling DEXA bone-density screening with product subscriptions. The company has raised approximately $36M+ in disclosed equity capital across a 2018 seed round, a 2020 Series A (~$11.2M), a 2023 Series B first close of $15M led by S2G Ventures (targeting up to $25M), and additional SEC exempt-offering filings of $1M (2024) and $9.91M (2025), supplemented by a $3M NIH/National Institute on Aging grant. Management is led by CEO Catherine Balsam-Schwaber (appointed October 2025), with co-founder Eric Schott, PhD as COO and scientific leadership under VP of R&D Mark Charbonneau, PhD; the company employs 11–50 people and is preparing to launch Arthrīva, a second synbiotic medical food for rheumatoid arthritis, in Spring 2026.

Solarea Bio firmographics

Firmographics
Name
Solarea Bio
Legal name
Sōlaria Biō, Inc.
Website
https://solareabio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Solarea Bio is a privately held biotechnology company that develops FDA-classified synbiotic medical foods from plant-sourced microbes; it sells Bōndia, a clinically validated bone-health product, via DTC subscription and a practitioner affiliate channel to postmenopausal and osteopenic women in the United States.
Ownership category
akta.pro rank

Solarea Bio industry classification

Industry
Product category
Medical Foods / Synbiotic Supplements
NAICS
Fruit and Vegetable Canning, Pickling, and Drying (31142)
SIC
Food And Kindred Products (2000)
akta.pro industry
PRIMARYAFAKAJAD
Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium)
Agriculture & Food Production/Food Processing & Manufacturing/Specialty & Functional Foods Manufacturing (Organic, Fortified, Medical Foods)

Keywords

  • Medical foods
  • Synbiotic supplements
  • Bone health products
  • Microbial therapeutics
  • Gut-bone axis

Where Solarea Bio is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Solarea Bio business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Direct-to-Consumer Product Sales: Primary revenue stream from selling Bōndia synbiotic medical food directly to consumers through the company's e-commerce website. Products available as one-time purchases or subscription plans with recurring billing. Subscription model provides predictable recurring revenue with discounts for longer commitments.
  2. One-Time Product Purchases: Single-month supply purchases available for consumers who prefer not to commit to subscriptions. Priced at $125/month for one-time buyers.
  3. Practitioner Affiliate Referrals: Healthcare providers earn commissions when they refer patients who purchase Bōndia through their unique affiliate link or code. Practitioners can apply to join the program and receive sample products to aid recommendations.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyMonthly subscription - $110/month
SubscriptionPay-as-you-go3-Month Supply - $94/month ($282 total)
SubscriptionAnnualAnnual Supply - $83/month ($999 total)
One time/ perpetual licensePay-as-you-goOne-Time Purchase - $125/month
SubscriptionAnnualGift Subscription - $999 (1-Year)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Solarea Bio product offering

Product offering

Core offering

Solarea Bio develops and sells FDA-regulated microbial medical foods. Its flagship product Bōndia is a plant-sourced synbiotic combining four proprietary probiotic strains with prebiotic fibers and algae-derived Vitamin D3, clinically proven to reduce bone loss in postmenopausal women via the gut-bone axis. The company sells direct-to-consumer via its website and through a practitioner affiliate channel.

Product overview

Solarea Bio (formerly Journa Health) is a biotechnology company offering a portfolio of microbial-based medical foods derived from beneficial microbes found in fruits and vegetables. The core product is Bōndia™, a plant-sourced synbiotic medical food clinically proven to reduce bone loss by targeting the gut-bone axis. The company is also developing Arthrīva, a product for rheumatoid arthritis expected in Spring 2026. Bōndia is positioned as a medical food (held to higher FDA safety and efficacy standards) rather than a dietary supplement, and is available via direct-to-consumer subscription through the company's Shopify-hosted website.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bōndia™ A plant-sourced, living synbiotic medical food designed to reduce bone loss in postmenopausal women by targeting the gut-bone axis. Contains four proprietary probiotic strains (Lactiplantibacillus plantarum SBS04260, Levilactobacillus brevis SBS04254, Leuconostoc mesenteroides SBS04255, Pichia kudriavzevii SBS04263) combined with prebiotic fibers from blueberry, chicory root, and algae-derived Vitamin D3. Sold as a medical food (FDA-regulated, higher standard than supplements) via direct-to-consumer subscription.

Quantifiable outcome

  • 85% reduction in femoral neck bone loss in women with osteopenia after 12 months of consistent use
  • +4 more outcomes

Companies that use Solarea Bio

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Solarea Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Solarea Bio partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

  • Harvard Medical SchoolflagshipStrategic or Co-development PartnerOngoing research partnership referenced in company materials. Clinical trial results and ongoing Harvard Medical School partnership reflect the company's commitment to uncompromising science and clinical validation.
  • DexaFitcoreStrategic or Co-development PartnerPartnership for bone density screening services. Offers bundled bone health packages combining DexaFit DEXA scans with Sōlaria Bio product subscriptions. Free DEXA scans included with product subscriptions at select locations.
  • Parsley HealthminorGTM or Marketing PartnerWellness healthcare provider featured as partner logo on website. Dr. Robin Berzin, Parsley Health founder, has spoken publicly about her personal osteopenia diagnosis and recommends Bōndia.
  • Aligned Modern HealthminorGTM or Marketing PartnerPartner logo displayed on company website, indicating a marketing or referral relationship with this wellness healthcare provider.
  • Wondr HealthminorGTM or Marketing PartnerPartner logo displayed on company website, indicating a marketing or referral relationship with this digital health platform.
  • Goal DailyminorGTM or Marketing PartnerPartner logo displayed on company website, indicating a marketing or referral relationship with this wellness brand.
  • mindbodygreenminorGTM or Marketing PartnerWellness media brand featured as partner logo on website, suggesting content marketing or referral partnership.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Solarea Bio competitors and assessment

Company assessment

Direct peers

  • Pendulum Therapeutics: Pendulum sells clinically validated, multi-strain synbiotic products via DTC subscription targeting specific conditions (e.g., metabolic health, glucose control). Closely comparable to Solarea Bio on proprietary probiotic strains, clinical evidence-based marketing, and direct subscription model.
  • Seed Health: Seed Health develops proprietary synbiotic formulations with patented strains and sells via DTC subscription. Comparable on proprietary-strain IP, science-forward branding, and subscription GTM, though Seed targets gut microbiome health more broadly than Solarea's indication-specific positioning.
  • Metagenics: Metagenics is a practitioner-channel medical food and supplement manufacturer with a strong focus on bone health, gut health, and inflammation. Closely comparable to Solarea Bio on FDA medical food positioning, practitioner/affiliate distribution model, and condition-specific functional foods.
  • Microbiome Labs: Microbiome Labs distributes practitioner-channel probiotic and microbiome products, including clinically studied formulations like Megasporebiotic. Comparable to Solarea Bio on practitioner/affiliate GTM and science-driven probiotic formulations.
  • Designs for Health: Designs for Health is a practitioner-channel supplement brand offering condition-specific protocols (including bone, gut, and inflammation). Comparable to Solarea Bio on practitioner affiliate distribution and clinician-focused selling motion.
  • Pure Encapsulations: Pure Encapsulations is a practitioner-grade supplement brand owned by Nestlé Health Science, sold through healthcare professionals with condition-specific lines. Comparable to Solarea Bio on practitioner-only distribution and hypoallergenic, science-led positioning.
  • Standard Process: Standard Process is a practitioner-channel whole-food supplement and medical food manufacturer. Comparable to Solarea Bio on practitioner distribution, condition-specific products, and medical food regulatory positioning.

Broad incumbents

  • Thorne: Thorne is a broad-line supplement brand sold through practitioners and DTC with strong clinical/athlete positioning. Comparable as a wider portfolio competitor in the practitioner-channel supplement market, though less indication-specific than Solarea Bio's medical food focus.
  • Nestlé Health Science: Nestlé Health Science is a global medical nutrition incumbent offering medical foods across bone, digestive, and metabolic health (e.g., Peptamen, Resource, Optifast). Comparable as a broad medical-foods incumbent against which Solarea competes for category share and physician mind-share.
  • Novonesis: Novonesis (formerly Chr. Hansen) is a global probiotic and enzyme ingredient manufacturer with deep microbial strain IP. Comparable as a broader ingredient/probiotic incumbent that controls much of the upstream strain supply Solarea Bio relies upon.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Solarea Bio social profiles

Digital presence

Solarea Bio compliance and trust

Trust signal

Compliance2 records

Solarea Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solarea Bio leadership team

Management profile

Number of profiles

Profiles4 records

Solarea Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solarea Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solarea Bio

What does Solarea Bio do?

Solarea Bio develops and sells FDA-regulated microbial medical foods. Its flagship product Bōndia is a plant-sourced synbiotic combining four proprietary probiotic strains with prebiotic fibers and algae-derived Vitamin D3, clinically proven to reduce bone loss in postmenopausal women via the gut-bone axis. The company sells direct-to-consumer via its website and through a practitioner affiliate channel.

Is Solarea Bio a public or private company?

Solarea Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Solarea Bio founded?

Solarea Bio was founded in 2017. It employs 11 to 50 people.

Where is Solarea Bio based?

Solarea Bio is headquartered in Waltham, United States, in the North America region.

How does Solarea Bio make money?

Three revenue lines are on record. Direct-to-Consumer Product Sales are the primary driver. The others are one-Time Product Purchases and practitioner Affiliate Referrals.

Who are Solarea Bio's main competitors?

Direct peers on record are Pendulum Therapeutics, Seed Health, Metagenics, Microbiome Labs, Designs for Health, Pure Encapsulations and Standard Process. Broad incumbents are Thorne, Nestlé Health Science and Novonesis.

Does Solarea Bio have an API?

No public API is recorded for Solarea Bio.

What industry is Solarea Bio in?

Solarea Bio's product category is Medical Foods / Synbiotic Supplements. Its primary akta.pro industry code is AFAKAJAD, Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium). Its NAICS code is 31142 and its SIC code is 2000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HrtodaySolarea Bio Appoints Catherine Balsam-Schwaber as Chief Executive OfficerSolarea Bio has appointed Catherine Balsam-Schwaber as its new Chief Executive Officer, succeeding founder Gerardo V. Toledo, Ph.D., who will transition to an advisory role. Under new leadership, the company is preparing to launch Bondia™, a first-of-its-kind synbiotic medical food designed to slow bone loss in postmenopausal women by targeting inflammation through the gut-bone axis. With nearly 70% of U.S. women over age 50 experiencing age-related bone loss, the product has potential market reach of over 45 million women nationwide.PR NewswireSolarea Bio Appoints New Chief Executive OfficerCatherine Balsam-Schwaber has been appointed Chief Executive Officer of Solarea Bio, a Boston-based biotechnology company focused on microbiome-based solutions for healthy aging, replacing founder Gerardo V. Toledo, Ph.D., who will transition to an advisory role. The company plans to commercially launch Bondia™, a first-of-its-kind synbiotic medical food for postmenopausal bone health, later this month (October 2025), targeting the approximately 45 million U.S. women over 50 who suffer from age-related bone loss.PR NewswireSolarea Bio to Showcase Innovations at 2025 Future Food-Tech SummitSolarea Bio will showcase its natural solutions for inflammatory conditions at the Future Food-Tech Summit in San Francisco on March 13-14. The company is a finalist in the Puratos Innovation Challenge, and CEO Gerardo Toledo will present on the gut microbiome and its product Bondia™ for osteopenia.SecSEC FORM DSolarea Bio, Inc. filed a Form D with the Securities and Exchange Commission to announce an exempt offering of equity securities under Rule 506(b), with the first sale occurring on August 27, 2024. The company disclosed a total offering amount of $1,000,000 USD and reported that one investor has already participated in the offering.PR NewswireIlissa Larimore Appointed Chief Commercial Officer at Solarea BioSolarea Bio, a Boston-based biotechnology company focused on health solutions derived from the edible plant microbiome, announced the appointment of Ilissa Larimore as Chief Commercial Officer. Larimore brings over 20 years of consumer health experience, having held executive roles at Pfizer and a 14-year tenure at Metagenics where she oversaw commercial operations. The company is preparing to enter the commercial stage with the launch of its Journa™ consumer health brand and its first product, Bondia™ synbiotic, a medical food designed for dietary management of bone loss in menopausal women.PR NewswireSolarea Bio Announces the Beta Launch of Bondia™, a Novel Daily Medical Food Helping Menopausal Women Manage Bone LossSolarea Bio, a Boston-based clinical-stage biotechnology company, announced the beta launch of Bondia™, a daily synbiotic medical food capsule designed to help peri- and postmenopausal women manage bone loss, with a public launch anticipated for September 2024. The product is currently undergoing a double-blind, placebo-controlled clinical trial involving 286 early postmenopausal women and has received Generally Recognized as Safe (GRAS) status. Beta participants will receive free Bondia™ capsules, access to the Journa mobile app, and Complete Beta Journey participants will also get complimentary full-body DEXA scans through a partnership with DexaFit in the San Francisco Bay area.YahooSolarea Bio Announces the Beta Launch of Bondia™, a Novel Daily Medical Food Helping Menopausal Women Manage Bone LossSolarea Bio launched its private beta program for Bondia, a daily synbiotic medical food for peri- and postmenopausal women to manage bone loss. The beta includes a DEXA scan, a year of capsules, and app access, with a public launch expected in September. The product is GRAS and undergoing a clinical trial in 286 women.HeadtopicsNIH awards $3 million grant to study synbiotic medical food for bone health in older womenThe NIH/National Institute on Aging has awarded a $3 million grant to study a synbiotic medical food developed by Solarea Bio for maintaining bone health in older women. The 18-month clinical trial will involve 220 participants and aims to test the efficacy of the product in maintaining lumbar spine bone mineral density with aging. The study addresses the significant health and economic impact of osteoporotic fractures in aging populations.Pulse 2.0Solarea Bio: $15 Million Raised For Developing Food-Derived Microbial-Based SolutionsSolarea Bio secured an initial $15 million in Series B financing led by S2G Ventures to support the commercial launch of two medical foods targeting bone health and rheumatoid arthritis. The funding, part of a $25 million target round, will facilitate the rollout of products developed from food-derived microbial consortia, with one product already showing efficacy in preclinical models.